Dual role of quercetin in enhancing the efficacy of cisplatin in chemotherapy and protection against its side effects: a review.
Sign Up to like & getrecommendations! Published in 2020 at "Archives of physiology and biochemistry"
DOI: 10.1080/13813455.2020.1773864
Abstract: Chemotherapy has opened a new window in cancer therapy. However, the resistance of cancer cells has dramatically reduced the efficacy of chemotherapy. Cisplatin is a chemotherapeutic agent and its potential in cancer therapy has been… read more here.
Keywords: chemotherapy; tumour activity; efficacy; cancer ... See more keywords
Polycaprolactone nanofibres loaded with 20(S)-protopanaxadiol for in vitro and in vivo anti-tumour activity study
Sign Up to like & getrecommendations! Published in 2018 at "Royal Society Open Science"
DOI: 10.1098/rsos.180137
Abstract: In this work, 20(S)-protopanaxadiol (PPD)-loaded polycaprolactone (PCL) nanofibres were successfully fabricated by the electrospinning technique using Tween 80 as a solubilizer. Firstly, smooth and continuous nanofibres were collected using suitable solvents and appropriate spinning conditions.… read more here.
Keywords: tumour activity; vitro vivo; vivo anti; drug ... See more keywords
Curcuminoid EF24 enhances the anti‐tumour activity of Akt inhibitor MK‐2206 through ROS‐mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Pharmacology"
DOI: 10.1111/bph.13765
Abstract: Gastric cancer is one of the leading causes of morbidity and mortality worldwide. Akt is an anti‐apoptotic kinase that plays a dynamic role in cell survival and is implicated in the pathogenesis of gastric cancer.… read more here.
Keywords: tumour activity; inhibitor; gastric cancer; cancer ... See more keywords
A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Pharmacology"
DOI: 10.1111/bph.15301
Abstract: Savolitinib (AZD6094, HMPL‐504, volitinib) is an oral, potent, and highly MET receptor TK inhibitor. This series of studies aimed to develop a pharmacokinetic–pharmacodynamic (PK/PD) model to link inhibition of MET phosphorylation (pMET) by savolitinib with… read more here.
Keywords: tumour activity; inhibitor; pharmacodynamic model; pharmacokinetic pharmacodynamic ... See more keywords